<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/9605308#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:Pathway rdf:ID="Pathway2">
 <bp:pathwayOrder rdf:resource="#PathwayStep5" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayComponent rdf:resource="#Pathway4" />
 <bp:pathwayComponent rdf:resource="#Pathway3" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Base Excision Repair Associated with NTHL1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NTHL1 is a DNA N-glycosylase that catalyzes the first step in base excision repair (BER), the primary repair pathway for oxidative DNA damage. NTHL1 can recognize and remove oxidized cytosine, adenine and thymine, in the form of cytosine glycol (Cg), 4,6-diamino-5-formamidopyrimidine (FapyA), and thymine glycol (Tg), respectively. NTHL1 can also recognize and remove dihydrouracil (DHU), produced by cytosine deamination. Germline mutations that impair function of NTHL1 predispose affected patients to a cancer syndrome (NTHL1 syndrome) that involves adenomatous polyposis and colorectal cancer, similar to MUTYH-associated polyposis (MAP), but also causes development of tumors in other organs, such as breast, bladder, skin, uterus and brain. Only patients with mutations in both alleles of NTHL1 are affected, indicative of an autosomally recessive inheritance (Weren et al. 2015, Rivera et al. 2015, Broderick et al. 2017, Grolleman et al. 2019). Some common NTHL1 polymorphisms may results in reduced NTHL1 function, but predisposition of affected individuals to cancer has not been studied in full (Galick et al. 2013). Mice that are double knockout for Neil1 and Nthl1 genes accumulate DNA damage in the form of FapyA and FapyG and are more prone to development of lung adenocarcinoma than single Neil1 or Nthl1 gene knockouts (Chan et al. 2009). Biallelic loss-of-function mutations in NTHL1 result in a mutational signature characterized by C&gt;T transitions at non-CpG sites (Grolleman et al. 2019). For review, please refer to Weren et al. 2018. Besides loss-of-function mutations, NTHL1 is amplified and overexpressed in some cancers. NTHL1 overexpression leads to genomic instability in non-transformed human bronchial epithelial cells and may lead to malignant transformation (Limpose et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway11">
 <bp:pathwayOrder rdf:resource="#PathwayStep25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction15" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence25" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OGG1 Localization</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">OGG1 splicing isoform beta contains a mitochondrial targeting sequence at the N terminus and lacks the C terminal nuclear localization signal. OGG1beta localizes to mitochondria (Nishioka et al. 1999), where it might participate in the repair of mitochondrial DNA, although its role in mitochondrial base excision repair has not been confirmed. OGG1beta G12E mutant, reported in kidney cancer, is unable to translocate to the mitochondrion as the missense mutation disrupts the mitochondrial targeting sequence (Audebert et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep16" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayOrder rdf:resource="#PathwayStep30" />
 <bp:pathwayOrder rdf:resource="#PathwayStep10" />
 <bp:pathwayOrder rdf:resource="#PathwayStep21" />
 <bp:pathwayComponent rdf:resource="#Pathway2" />
 <bp:pathwayComponent rdf:resource="#Pathway13" />
 <bp:pathwayComponent rdf:resource="#Pathway6" />
 <bp:pathwayComponent rdf:resource="#Pathway5" />
 <bp:pathwayComponent rdf:resource="#Pathway9" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of Base Excision Repair</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Germline mutations, single nucleotide polymorphisms (SNPs) and somatic mutations in several genes involved in base excision repair (BER), a DNA repair pathway where a damaged DNA base is excised and replaced with a correct base, are involved in the development of cancer and several other oxidative stress-related diseases. For review, please refer to Fu et al. 2012, Fletcher and Houlston 2010, Brenerman et al. 2014, Patrono et al. 2014, and D&apos;Errico et al. 2017.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway10">
 <bp:pathwayOrder rdf:resource="#PathwayStep23" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction14" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence23" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OGG1 Substrate Binding</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">OGG1 missense mutants reported in Alzheimer&apos;s disease, OGG1 A53T and OGG1 A288V, show decreased binding to 8 oxoguanine substrate (Mao et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway4">
 <bp:pathwayOrder rdf:resource="#PathwayStep9" />
 <bp:pathwayOrder rdf:resource="#PathwayStep6" />
 <bp:pathwayOrder rdf:resource="#PathwayStep7" />
 <bp:pathwayOrder rdf:resource="#PathwayStep8" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction6" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence6" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NTHL1 substrate binding</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Several different mutations that result in truncation of NTHL1 protein have been described and associated with cancer. NTHL1 Q90TER (NTHL1 Gln90*) truncation mutant results from a nonsense mutation that replaces codon for glutamine 90 with a STOP codon. NTHL1 Q90TER has not been studied at the protein level, but is predicted to lack the DNA binding domain and the glycosylase domain, thus resulting in a complete loss of the base excision repair (BER) related DNA glycosylase function. Homozygous or compound heterozygous germline NTHL1 Q90TER mutation result in a cancer syndrome (NTHL1 associated tumor syndrome) that involves adenomatous polyposis, colorectal cancer breast cancer and multiple other types of cancer and benign tumors (Weren et al. 2015, Rivera et al. 2015, Grolleman et al. 2019). Apart from NTHL1 Q90TER, at least seven other truncating variants have been identified in patients with NTHL1 associated tumor syndrome, such as NTHL1 A79fs (NTHL1 Ala79fs), NTHL1 Y130TER (NTHL1 Tyr130*), NTHL1 W182TER (NTHL1 Trp182*), NTHL1 c.709+1G&gt;A, NTHL1 I245fs (NTHL1 Ile245fs), NTHL1 W269TER (NTHL1 Trp269*), NTHL1 Q287TER (NTHL1 Gln287*) (Rivera et al. 2015, Broderick et al. 2017, Grolleman et al. 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway13">
 <bp:pathwayOrder rdf:resource="#PathwayStep31" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction19" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence31" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Base Excision Repair Associated with NEIL3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEIL3 is a DNA N-glycosylase involved in base excision repair (BER), the primary repair pathway for oxidative DNA damage. NEIL3 can detect and remove oxidized guanine, in the form of 5-guanidinohydatoin and spiroiminodihydantoin, and oxidized thymine, in the form of thymine glycol. NEIL3 has a preference for single strand DNA (ssDNA) and is implicated in repair of oxidative DNA damage at telomeres (Zhou et al. 2013). A NEIL3 disease variant NEIL3 D132 is unable to cleave 5 guanidinohydantoin (Gh) from oxidatively damaged DNA. Individuals harboring a NEIL3 D132V homozygous mutation are predisposed to development of autoimmune diseases (Massaad et al. 2016) and NEIL3 depletion is also associated with an increase in telomere damage and loss (Zhou et al. 2017). NEIL3 unhooks DNA interstrand cross-links (ICLs) during DNA replication. NEIL3 resolves psoralen- and abasic site-induced ICLs in a Fanconi anemia (FA) pathway-independent manner (Semlow et al. 2016, Martin et al. 2017). A polymorphism in one of the NEIL3 gene splice sites may increase the risk of myocardial infarction (Skarpengland et al. 2015). NEIL3 expression in the heart increases after heart failure in humans and after myocardial infarction in mouse disease models. Neil3 knockout mice show increased mortality after myocardial infarction, but there is no increase in the amount of DNA damage in Neil3 knockout hearts. In the heart, NEIL3 may function in the epigenetic regulation of gene expression and facilitate transcriptional response to myocardial infarction (Olsen et al. 2017). NEIL3 mRNA expression is increased in human carotid plaques and Neil3 deficiency accelerates plaque formation in Apoe knockout mice, but it appears that this is not correlated with oxidative DNA damage (Skarpengland et al. 2016). The function of NEIL3 in removal of hydantoins from single strand DNA may be important for removal of replication blocks in proliferating cells. Mouse embryonic fibroblasts and neuronal stem cell derived from Neil3 knockout mouse embryos show decreased proliferation capacity and increased sensitivity to DNA damaging agents (Rolseth et al. 2013). NEIL3 may be required for maintenance of adult neurogenesis, as Neil3 knockout mice exhibit learning and memory deficits and synaptic irregularities in the hippocampus (Regnell et al. 2012). In addition, NEIL3 deficient neuronal stem cells exhibits signs of premature senescence (Reis and Hermanson 2012) and Neil3 knockout mice show reduced ability to augment neurogenesis to repair damage induced hypoxia ischemia (Sejersted et al. 2011). Mice that are triple knockout for Neil1, Neil2 and Neil3 do not show a predisposition to tumour formation or changes in telomere length (Rolseth et al. 2017). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway3">
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NTHL1 substrate processing</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NTHL1 D239Y is produced as a consequence of a single nucleotide polymorphism (SNP) rs3087468 in the NTHL1 gene. The frequency of this polymorphism varies in different populations. Substitution of aspartic acid residue at position 239 with tyrosine results in an NTHL1 protein that is still able to bind to damaged DNA but appears to have impaired glycosylase activity. Expression of NTHL1 D239Y in non-transformed human and mouse mammary epithelial cells increases genomic instability and leads to neoplastic transformation, acting as a dominant negative for wild-type NTHL1, through competition for substrate binding (Galick et al. 2013). It is uncertain if heterozygosity for NTHL1 D239Y polymorphism increases predisposition to cancer.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway12">
 <bp:pathwayOrder rdf:resource="#PathwayStep27" />
 <bp:pathwayOrder rdf:resource="#PathwayStep28" />
 <bp:pathwayOrder rdf:resource="#PathwayStep29" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction16" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction18" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction17" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence27" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OGG1 Substrate Processing</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The majority of OGG1 mutants have been tested for their ability to excise 8-oxoguanine (8oxoG) from damaged DNA, while a small number of mutants have been tested for the ability to remove FapyG from DNA. The following OGG1 mutants show at least a partial loss of their ability to remove 8oxoG: OGG1 R46Q (Audebert, Chevillard et al. 2000; Audebert, Radicella et al. 2000); OGG1 R154H (Audebert, Radicella et al. 2000, Bruner et al. 2000); OGG1 R131Q (Chevillard et al. 1998, Bruner et al. 2000, Anderson and Dagget 2009); OGG1 R229Q (Hyun et al. 2000, Hyun et al. 2002, Hill and Evans 2007); OGG1 P266fs139* (Mao et al. 2007). OGG1 R46L and OGG1 R131G have not been functionally studied but have been reported in cancer and predicted to be pathogenic. They are annotated as candidate disease variants based on their similarity with OGG1 R46Q and OGG1 R131Q, respectively. OGG1 S326C, a frequent variant in European and Asian populations, is susceptible to oxidation, which diminishes catalytic activity under conditions of oxidative stress (Dherin et al. 1999, Yamane et al. 2004, Kershaw and Hodges 2012, Moritz et al. 2014). The following OGG1 mutants show at least a partial loss of their ability to remove FapyG: OGG1 R46Q (Audebert, Radicella et al. 2000); OGG1 R154H (Audebert, Radicella et al. 2000). OGG1 R46L has not been functionally studied but has been reported in cancer and predicted to be pathogenic. It is annotated as a candidate disease variant for FapyG excision, based on its similarity with OGG1 R46Q.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway6">
 <bp:pathwayOrder rdf:resource="#PathwayStep17" />
 <bp:pathwayOrder rdf:resource="#PathwayStep19" />
 <bp:pathwayComponent rdf:resource="#Pathway8" />
 <bp:pathwayComponent rdf:resource="#Pathway7" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence17" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Base Excision Repair Associated with MUTYH</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MUTYH gene is located on chromosome 1 and encodes a DNA glycosylase involved in base excision repair (BER). MUTYH (MYH) functions as an adenine DNA glycosylase and removes adenines and 2-hydroxyadenines on the newly synthesized DNA strand mispaired with guanines or 8-oxoguanines. 8-oxogunanines are produced by oxidation of guanines in DNA or by incorporation of 8-oxodGTP from the nucleotide pool into the newly synthesized DNA strand. Germline mutations in MUTYH cause the MUTYH-associated polyposis (MAP), a syndrome that resembles the familial adenomatous polyposis (FAP) syndrome, caused by mutations in the APC tumor suppressor gene. MAP is also known as the familial adenomatous polyposis 2 (FAP2) (OMIM:608456). MAP-affected individuals are predisposed to development of multiple colorectal adenomas and colorectal cancer. MAP is largely inherited in an autosomally recessive manner, with both MUTYH alleles affected. The predisposition of heterozygous MUTYH mutation carriers to MAP has not been completely ruled out (Fleischmann et al. 2004).  MUTYH is most frequently affected by missense mutations in MAP patients, with two major mutations, Y165C and G382D, reported in about 80% of MAP patients of European origin. In Japanese patients, the most frequently reported mutation was Q324H (Yanaru-Fujisawa et al. 2008). Residues Y165C and G382D in the abundant MUTYH isoform MUTYH alpha-3 (MUTYH-3), used in the majority of functional studies, correspond to Y176C and G393D, respectively, in the canonical UniProt isoform (MUTYH alpha-1) and to Y179C and G396, respectively, in the longest NCBI isoform, which is used as a reference isoform in the database InSiGHT (International Society for Gastrointestinal Hereditary Tumours Database). However, both the canonical UniProt and NCBI MUTYH isoforms are expressed at very low levels or not at all (Plotz et al. 2012). In addition to the isoform MUTYH alpha-3, the other two abundant MUTYH isoforms are MUTYH beta-3 and MUTYH gamma-3 (Plotz et al. 2012), which differ from MUTYH alpha-3 in the first exon used. Exons 1-alpha and 1-beta contain sequences that resemble a mitochondrial targeting signal (MTS). It was reported that MUTYH alpha-3 and MUTYH beta-3 predominantly localize to mitochondria, while MUTYH gamma-3 predominantly localizes to the nucleus (Takao et al. 1999). However, a nuclear localization signal is located at the C-terminus of all MUTYH isoforms and other studies suggested that all isoforms can localize to the nucleus and only a small fraction of MUTYH is targeted to the mitochondria (Ohtsubo et al. 2000, Ichinoe et al. 2004). A small number of functional studies of MUTYH mutants uses the MUTYH isoform gama-3 (Goto et al. 2010, Shinmura et al. 2012). Nuclear localization of MUTYH may be affected by a splicing site variant (Tao et al. 2004).  MAP, compared with APC-associated FAP, is characterized by a later age of onset and a smaller number and size of polyps. Germline MUTYH mutations are associated with an increased incidence of duodenal polyps, gastric cancer, melanoma, breast cancer, dental and dermoid cysts, and osteomas. MUTYH mutations are rarely reported in the sporadic colorectal cancer. Tumors that develop in MAP patients are characterized with an excess of G:C -&gt; T:A transversions in tumor suppressor genes, such as APC, and oncogenes, such as KRAS, which is a consequence of MUTYH functional impairment.  A single nucleotide polymorphism (SNP) at the splice donor site was reported to affect translation efficiency of MUTYH transcript, but its relevance for cancer predisposition has not been clarified (Yamaguchi et al. 2002). Catalytic activity of MUTYH and its mutants may be affected by posttranslational modifications (Parker et al. 2003, Kundu et al. 2010). Some MUTYH mutations reported in colorectal cancer do not affect MUTYH catalytic activity but disrupt the interaction of MUTYH with other proteins involved in DNA repair (Tominaga et al. 2004, Turco et al. 2013).  For review, please refer to Chow et al. 2004, Nielsen et al. 2011, Venesio et al. 2012, Mazzei et al. 2013.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway5">
 <bp:pathwayOrder rdf:resource="#PathwayStep14" />
 <bp:pathwayOrder rdf:resource="#PathwayStep15" />
 <bp:pathwayOrder rdf:resource="#PathwayStep11" />
 <bp:pathwayOrder rdf:resource="#PathwayStep12" />
 <bp:pathwayOrder rdf:resource="#PathwayStep13" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction10" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction11" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction8" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction9" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence11" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Base Excision Repair Associated with NEIL1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEIL1 is an enzyme with dual DNA glycosylase and beta/delta lyase activity involved in base excision repair pathway (BER), the primary repair pathway for oxidative DNA damage. NEIL1 can detect and remove DNA damage resulting from oxidation of adenine, guanine and thymine, in the form of 4,6-diamino-5-formamidopyrimidine (FapyA), 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyG), and thymine glycol (Tg), respectively. NEIL1 can also detect and remove dihydrouracil (DHU), which results from deamination of cytosine. Several low frequency NEIL1 polymorphisms, present in about 1% of general population in the United States have been reported. Different polymorphisms have different effects on NEIL1 function, and it was suggested that NEIL1 polymorphisms and NEIL1 deficiency or haploinsuficiency may be involved in predisposition to cancer and in metabolic syndrome (Roy et al. 2007, Vartanian et al. 2006, Sampath et al. 2011, Prakash et al. 2014). One polymorphism, NEIL1 G83D, is associated with primary sclerosing cholangitis and cholangiocarcinoma (Forsbring et al. 2009). NEIL1 G83D variant exhibits impaired DNA glycosylase activity towards different damaged DNA bases (Roy et al. 2007, Prakash et al. 2014) and induces genomic instability (Galick et al. 2017). NEIL1 E28del, an in frame deletion variant of NEIL1 reported in gastric (stomach) cancer, where glutamate at position 28 is deleted, does not cleave Tg from damaged DNA (Shinmura et al. 2004). NEIL1 Q282TER, a NEIL1 variant which lacks the putative nuclear localization signal (NLS), localizes to the cytosol and is therefore not able to access damaged DNA substrates, but its involvement in cancer is uncertain (Shinmura et al. 2015). Reduced expression of NEIL1 and NEIL2 genes, accompanied with increased NEIL3 gene expression was detected in various cancers. NEIL1 gene silencing by promoter hypermethylation may be one of the underlying mechanisms for reduced NEIL1 expression in cancer (Shinmura et al. 2016). Infection with the Hepatitis C virus (HCV) leads to decreased NEIL1 expression in liver cells, through an unknown mechanism (Pal et al. 2010). Mice that are double knockout for Neil1 and Nthl1 genes accumulate DNA damage in the form of FapyA and FapyG and are more prone to development of lung adenocarcinoma than single Neil1 or Nthl1 gene knockouts (Chan et al. 2009). Another study reported that Neil1 knockout mice did not show a predisposition to tumour formation, and neither did double knockouts of Neil1 and Neil2, nor triple knockouts of Neil1, Neil2 and Neil3. Neil1 knockout mice are obese, consistent with the metabolic syndrome, but double knockouts of Neil1 and Neil2 do not display obesity (Rolseth et al. 2017). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway8">
 <bp:pathwayOrder rdf:resource="#PathwayStep20" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction13" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence20" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MUTYH substrate processing</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MUTYH disease variants underlying the MUTYH-associated polyposis (MAP), also known as familial adenomatous polyposis 2 (FAP2), show impaired catalytic activity with respect to cleaving adenine mispaired with 8-oxoguanine (OGUA:Ade, also known as 8-oxoG:A). For some of the mutants, defective substrate processing is further aggravated by reduced substrate binding. MUTYH alpha-3 isoform (MUTYH-3) mutants and MUTYH gamma-3 isoform (MUTYH-6) mutants with experimentally demonstrated deficiency in catalytic activity include missense mutants MUTYH-3 Y165C (MUTYH-6 Y151C), MUTYH-3 R171W, MUTYH-3 R227W, MUTYH-3 R231H, MUTYH-3 R231L, MUTYH-3 V232F,  MUTYH-3 R260Q, MUTYH-3 G272E, MUTYH-3 P281L, MUTYH-3 P391L (MUTYH-6 P377L), MUTYH-3 Q324H, MUTYH-3 Q324R,, MUTYH-3 A359V, MUTYH-3 G382D (MUTYH-6 G368D), MUTYH-3 A459D, MUTYH-6 R154H, MUTYH-6 I195V, MUTYH-6 M255V and MUTYH-3 L360P, in-frame indel mutants MUTYH-3 W138_M139insIW (also known as MUTYH 137insIW) and MUTYH-3 E466del (MUTYH-6 E452del), nonsense mutants MUTYH-3 Y90*, MUTYH-3 Q377*, and MUTYH-3 E466*, and frameshift mutant MUTYH-3 A368fs26* (commonly known as MUTYH 1103delC) (Jones et al. 2002, Chmiel et al. 2003, Wooden et al. 2004, Parker et al. 2005, Bai et al. 2005, Alhopuro et al. 2005, Bai et al. 2007, Ali et al. 2008, Yanaru-Fujisawa et al. 2008, Kundu et al. 2009, Forsbring et al. 2009, Molatore et al. 2010, D&apos;Agostino et al. 2010, Goto et al. 2010, Raetz et al. 2012, Shinmura et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway7">
 <bp:pathwayOrder rdf:resource="#PathwayStep18" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction12" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence18" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MUTYH substrate binding</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">For a subset of MUTYH disease variants underlying MUTYH-associated polyposis (MAP), also known as familial adenomatous polyposis 2 (FAP2), it was shown that, in addition to impaired catalytic activity, they also exhibit reduced binding to their substrate, adenine mispaired with 8-oxoguanine (OGUA:Ade, also known as 8-oxoG:A). MUTYH alpha-3 isoform (MUTYH-3) mutants with demonstrated deficient binding to OGUA:Ade include missense variants MUTYH-3 Y165C, MUTYH-3 R227W, MUTYH-3 R231L, MUTYH-3 R231H, MUTYH-3 V232F, MUTYH-3 R260Q, MUTYH-3 P281L and MUTYH-3 G382D, nonsense variants MUTYH-3 Y90*, MUTYH-3 Q377*, MUTYH-3 E466*, and frameshift variant MUTYH-3 A368fs26* (commonly known as MUTYH 1103delC) (Chmiel et al. 2003, Parker et al. 2005, Ali et al. 2008, Molatore et al. 2010, D&apos;Agostino et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway9">
 <bp:pathwayOrder rdf:resource="#PathwayStep26" />
 <bp:pathwayOrder rdf:resource="#PathwayStep22" />
 <bp:pathwayOrder rdf:resource="#PathwayStep24" />
 <bp:pathwayComponent rdf:resource="#Pathway11" />
 <bp:pathwayComponent rdf:resource="#Pathway10" />
 <bp:pathwayComponent rdf:resource="#Pathway12" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence22" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Base Excision Repair Associated with OGG1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">OGG1 is the main DNA glycosylase responsible for removal of 8-oxoguanine (8oxoG), the most frequent type of oxidative DNA damage, from DNA and initiation of the base excision repair (Klungland et al. 1999, Minowa et al. 2000). A frequent OGG1 polymorphism increases the risk of breast and lung cancer in affected individuals, and inactivating mutations in OGG1 have been reported in various cancer types and in Alzheimer&apos;s disease. Ogg1 knockout mice are predisposed to cancer. For review, please refer to Boiteux et al. 2017. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NTHL1 D239Y does not cleave dihydrouracil (DHU)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence7" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NTHL1 truncation mutants do not bind dihydrouracil (DHU)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence8" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NTHL1 truncation mutants do not bind formamidopyrimidine (FapyA)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction5">
 <bp:evidence rdf:resource="#Evidence9" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NTHL1 truncation mutants do not bind cytosine glycol (Cg)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction6">
 <bp:evidence rdf:resource="#Evidence10" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NTHL1 truncation mutants do not bind thymine glycol (Tg)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction7">
 <bp:evidence rdf:resource="#Evidence12" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEIL1 Q282TER does not translocate to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction8">
 <bp:evidence rdf:resource="#Evidence13" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NEIL1 variants do not cleave Tg</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction9">
 <bp:evidence rdf:resource="#Evidence14" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEIL1 G83D does not cleave FapyA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep30">
 <bp:stepProcess rdf:resource="#Pathway13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep31">
 <bp:stepProcess rdf:resource="#BiochemicalReaction19" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NTHL1 D239Y does not cleave thymine glycol (Tg)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence9">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep25">
 <bp:stepProcess rdf:resource="#BiochemicalReaction15" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence8">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep26">
 <bp:stepProcess rdf:resource="#Pathway12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep27">
 <bp:stepProcess rdf:resource="#BiochemicalReaction16" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep28">
 <bp:stepProcess rdf:resource="#BiochemicalReaction17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep29">
 <bp:stepProcess rdf:resource="#BiochemicalReaction18" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence30">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence32">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence31">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence7">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence6">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep20">
 <bp:stepProcess rdf:resource="#BiochemicalReaction13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep21">
 <bp:stepProcess rdf:resource="#Pathway9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep22">
 <bp:stepProcess rdf:resource="#Pathway10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep23">
 <bp:stepProcess rdf:resource="#BiochemicalReaction14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep24">
 <bp:stepProcess rdf:resource="#Pathway11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep14">
 <bp:stepProcess rdf:resource="#BiochemicalReaction10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep15">
 <bp:stepProcess rdf:resource="#BiochemicalReaction11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep16">
 <bp:stepProcess rdf:resource="#Pathway6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep17">
 <bp:stepProcess rdf:resource="#Pathway7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep18">
 <bp:stepProcess rdf:resource="#BiochemicalReaction12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep19">
 <bp:stepProcess rdf:resource="#Pathway8" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence19">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence12">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence11">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence14">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence13">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep10">
 <bp:stepProcess rdf:resource="#Pathway5" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence16">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep11">
 <bp:stepProcess rdf:resource="#BiochemicalReaction7" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence15">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep12">
 <bp:stepProcess rdf:resource="#BiochemicalReaction8" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence18">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep13">
 <bp:stepProcess rdf:resource="#BiochemicalReaction9" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence17">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep9">
 <bp:stepProcess rdf:resource="#BiochemicalReaction6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep5">
 <bp:stepProcess rdf:resource="#Pathway4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep6">
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep7">
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence10">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep8">
 <bp:stepProcess rdf:resource="#BiochemicalReaction5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Pathway2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#Pathway3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence23">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence22">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence25">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence24">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence27">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence26">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence29">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence28">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence21">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence20">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction10">
 <bp:evidence rdf:resource="#Evidence15" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEIL1 G83D does not cleave FapyG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction12">
 <bp:evidence rdf:resource="#Evidence19" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MUTYH mutants do not bind adenine mispaired with 8-oxoguanine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction11">
 <bp:evidence rdf:resource="#Evidence16" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEIL1 G83D does not cleave DHU</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction14">
 <bp:evidence rdf:resource="#Evidence24" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OGG1 mutants show decreased binding to 8-oxoguanine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction13">
 <bp:evidence rdf:resource="#Evidence21" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MUTYH mutants do not cleave adenine mispaired with 8-oxoguanine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction16">
 <bp:evidence rdf:resource="#Evidence28" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OGG1 mutants do not excise FapyG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction15">
 <bp:evidence rdf:resource="#Evidence26" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">OGG1beta G12E does not translocate to mitochondria</bp:displayName>
</bp:BiochemicalReaction>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction18">
 <bp:evidence rdf:resource="#Evidence30" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OGG1 mutants do not excise 8-oxoguanine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction17">
 <bp:evidence rdf:resource="#Evidence29" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">OGG1 S326C is oxidized</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction19">
 <bp:evidence rdf:resource="#Evidence32" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEIL3 D132V does not cleave 5-guanidinohydantoin (Gh)</bp:displayName>
</bp:BiochemicalReaction>
</rdf:RDF>